Table 35Fractures with bisphosphonates relative to raloxifene

Author, YearStudy DurationFracture TypeNumber of Fractures, BisphosphonateNumber of Fractures, RaloxifeneOdds Ratio (95% CI)
Alendronate
Total Fractures
Original 2007 Report
Luckey, 200423312 monthsAll clinical5/2218/2300.65 (0.22, 1.95)
Uchida, 200523412 monthsVertebral or nonvertebral22/71320/6991.08 (0.59, 2.0)
Update Report: No new studies
Vertebral Fractures
Original 2007 Report
Muscoso, 200423524 monthsVertebral6/1,0000/100NC
Uchida, 200523412 monthsVertebral8/7135/6991.56 (0.52, 4.65)
Update Report: No new studies
Nonvertebral Fractures
Original 2007 Report
Uchida, 200523412 monthsNonvertebral14/71315/6990.94 (0.44, 1.91)
Update Report: No new studies
Hip Fractures
Original 2007 Report
Muscoso, 200423524 monthsFemoral3/1,0000/100NC
Uchida, 200523412 monthsHip1/7132/6990.5 (0.05, 4.84)
Update Report: No new studies
Wrist Fractures
Original 2007 Report
Muscoso, 200423524 monthsRadial1/1,0000/100NC
Uchida, 200523412 monthsWrist6/7138/6990.74 (0.26, 2.11)
Update Report: No new studies
Risedronate
Vertebral Fractures
Original 2007 Report
Muscoso, 200423524 monthsVertebral0/1000/100NC
Update Report: No new studies
Hip Fractures
Original 2007 Report
Muscoso, 200423524 monthsFemoral0/1000/100NC
Update Report: No new studies
Wrist Fractures
Original 2007 Report
Muscoso, 200423524 monthsRadial0/1000/100NC
Update Report: No new studies

NC = not calculable

From: Results

Cover of Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet].
Comparative Effectiveness Reviews, No. 53.
Crandall CJ, Newberry SJ, Diamant A, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.